 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

SAN FRANCISCO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") announced today that it has entered into a definitive securities purchase...

Titan Pharmaceuticals Announces $9.5 Million Private Placement of Convertible Preferred Stock

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP  Get Free Report) crossed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $0.70...

Titan Pharmaceuticals (NASDAQ:TTNP) Share Price Passes Below Two Hundred Day Moving Average of $0.70

Investment analysts at StockNews.com assumed coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP  Get Free Report) in a report issued on Sunday. The brokerage set a sell&#8221...

Titan Pharmaceuticals (NASDAQ:TTNP) Coverage Initiated at StockNews.com

StockNews.com started coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP Free Report) in a research note published on Sunday. The firm issued a sell rating on the specialty pharmaceutical companys stock. Titan Pharmaceuticals Stock Up 8.1 % Shares of NASDAQ:TTNP opened at $0.55 on Friday. The ...

Titan Pharmaceuticals (NASDAQ:TTNP) Now Covered by Analysts at StockNews.com

Titan Pharmaceuticals (NASDAQ:TTNP Get Free Report) and Cullinan Oncology (NASDAQ:CGEM Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, ...

Contrasting Titan Pharmaceuticals (NASDAQ:TTNP) and Cullinan Oncology (NASDAQ:CGEM)

Investigating the valuation of Titan Pharmaceuticals Inc (TTNP) and its potential for future returnsRelated Stocks: TTNP...

Unveiling Titan Pharmaceuticals (TTNP)'s Value: Is It Really Priced Right? A Comprehensive Guide

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP  Get Free Report) saw a significant decline in short interest in the month of August. As of August 15th, there was short interest totalling 113,500...

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) Sees Large Decline in Short Interest

Research analysts at StockNews.com started coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP Get Free Report) in a research note issued on Saturday. The brokerage set a sell rating on the specialty pharmaceutical companys stock. Titan Pharmaceuticals Stock Up 0.7 % Shares of Titan ...

Titan Pharmaceuticals (NASDAQ:TTNP) Now Covered by StockNews.com

Research analysts at StockNews.com started coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP  Get Free Report) in a research note issued on Saturday. The brokerage set a sell rating on the specialty pharmaceutical companys stock. Titan Pharmaceuticals Stock Up 0.7...

Investment analysts at StockNews.com assumed coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP Get Free Report) in a note issued to investors on Friday. The brokerage set a sell rating on the specialty pharmaceutical companys stock. Titan Pharmaceuticals Price Performance NASDAQ TTNP opened ...

Titan Pharmaceuticals (NASDAQ:TTNP) Receives New Coverage from Analysts at StockNews.com

Titan Pharmaceuticals, Inc. engages in the development of therapeutics for the treatment of chronic diseases utilizing its long-term, continuous drug delivery platform, proNeura. Its lead product is probuphine, a buprenorphine implant for the maintenance treatment of opioid addiction. The company was founded by Louis R. Bucalo on February 7, 1992 and is headquartered in South San Francisco, CA.

Watchers	33,575
52-Wk Low	$0.428
52-Wk High	$1.24

Market Cap	$6.83M
Volume (M)	25,902.00
52-Wk High	$1.24
52-Wk Low	$0.428

Current Price	$0.4548
Prev Close	$0.458
Open	$0.44
Dividend Yield	0.00%
50-Day Moving Average	$0.5098
Beta	0.68
Avg. Volume	20,761.05
PE Ratio	-0.80

52-Week High	$1.24
52-Week Low	$0.428
Market Capitalization	$6.83M
EPS	-$0.5709
Price to Book	-6.60
Revenue Per Employee	$99,250.00
Enterprise Value/EBITDA	-1.16

TTNP Titan Pharmaceuticals, Inc. (de)

About

Feed

News

Fundamentals